Last reviewed 2026-04-19 · How we verify

GFF Inhalation Aerosphere

ShiYue Li · Phase 1 active Small molecule

GFF Inhalation Aerosphere is a Small molecule drug developed by ShiYue Li. It is currently in Phase 1 development. Also known as: Bevespi.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GFF Inhalation Aerosphere
Also known as	Bevespi
Sponsor	ShiYue Li
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GFF Inhalation Aerosphere CI brief — competitive landscape report
GFF Inhalation Aerosphere updates RSS · CI watch RSS
ShiYue Li portfolio CI

Frequently asked questions about GFF Inhalation Aerosphere

What is GFF Inhalation Aerosphere?

GFF Inhalation Aerosphere is a Small molecule drug developed by ShiYue Li.

Who makes GFF Inhalation Aerosphere?

GFF Inhalation Aerosphere is developed by ShiYue Li (see full ShiYue Li pipeline at /company/shiyue-li).

Is GFF Inhalation Aerosphere also known as anything else?

GFF Inhalation Aerosphere is also known as Bevespi.

What development phase is GFF Inhalation Aerosphere in?

GFF Inhalation Aerosphere is in Phase 1.

Manufacturer: ShiYue Li — full pipeline
Also known as: Bevespi

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing